Agios Pharmaceuticals, Inc. (AGIO) Earnings Call Transcript & Summary

May 5, 2022

NASDAQ US Health Care Biotechnology earnings 40 min

Earnings Call Speaker Segments

Holly Manning

executive
#1

Operator, thank you. Greetings, everyone, and good morning. We're delighted that you could be part of Agios' conference call for the first quarter of 2022. Today's presentation slides are available on our website, agios.com, under the Investors section. Presenting prepared remarks alongside me today are our Chief Executive Officer, Dr. Jackie Fouse; Dr. Sarah Gheuens, who serves as Chief Medical Officer; our Chief Commercial Officer, Richa Poddar; Jonathan Biller, our Chief Financial Officer and Head of Corporate Affairs; and Dr. Bruce Car, our Chief Scientific Officer, who will be available during Q&A. Prior to starting, I'd like to note that a number of the things we say during this call will contain forward-looking statements. Real outcomes might end up varying significantly from what any forward-looking statements suggest or imply, because of a range of risks, unknowns, and additional elements — among them the ones listed in the latest documents we filed with the SEC, plus any subsequent submissions we might file there. Having said that, I'll now hand things over to Jackie.

Jacqualyn Fouse

executive
#2

Appreciate that, Holly. Morning, everybody, and thanks for being here on our Q1 2022 results call. For Agios, the opening quarter of 2022 marked a pivotal point, since we secured U.S. FDA approval for PYRUKYND — a first-in-class PK activator, and the very first and only approved disease-modifying therapy for adults who are living with pyruvate kinase deficiency. From the researchers who initially proposed what PK activation might do, to the chemists behind our molecule's design, to the clinical trial coordinators who assisted in enrolling our studies, individuals throughout our company, past and present alike, contributed to reaching this significant milestone; beyond that, a great many people from outside our organization were essential to this work. Investigators, patients, caregivers and advocates — every one of them offered vital perspectives throughout each stage. Our bond with patients fighting this uncommon, debilitating, lifelong hemolytic anemia, together with the possibility of what we can bring to their treatment choices, is what drives us to show up for work daily, and our ties with patients, health care providers, partners and one another are how we turn this concept into a medicine. Going forward, we feel strongly motivated to carry out the U.S. adult PK deficiency launch as well as we possibly can, and our belief persists that PK activation holds wide potential past PK deficiency. One major priority for our team in 2022 is delivering on our ambitious clinical development plan, covering thalassemia, sickle cell disease, pediatric PK deficiency and MDS, and Sarah will walk through that in greater depth. I'm also happy to report that our 2022 Environmental, Social and Governance report has just been published. Back in 2020, we put out our initial ESG report, aiming to share pertinent ESG initiatives and metrics from throughout the company that align not just with our values and our culture, but additionally with the United Nations Sustainable Development Goals and the standards for the biotechnology and pharmaceutical industry established by the Sustainability Accounting Standards Board. From then on, our ESG program has expanded and developed as we keep prioritizing our commitments to the patients we serve, our employees, our communities and world and business ethics and values. We back and push forward a variety of ESG initiatives and invite you to take a look at our report, which you can find on our website agios.com in the Corporate Social Responsibility section. Many thanks to the cross-functional ESG Working Group for making this year's report a reality. To close, our commercial team is eagerly deep in the work of our U.S. adult PK deficiency launch, and Richard will bring you up to speed on that. Our clinical team is actively enrolling thalassemia and sickle cell patients into those pivotal programs, and Sarah will give you an update on them. Meanwhile, every one of our other functional teams is putting in hard work to help achieve our 2022 corporate objectives and our strategic vision. With that, I'll hand things over to Sarah.

Sarah Gheuens

executive
#3

Thank you, Jackie. Our clinical group has been putting in tremendous effort to carry out the ambitious development plan we set for 2022. First, I'll cover pyruvate kinase deficiency, where it makes us proud that we were the first to develop a therapy for this uncommon, lifelong hemolytic anemia. The marketing authorization applications for PYRUKYND in adult PK deficiency are still being reviewed in the EU, and we continue to expect a decision from the EMA by year-end. On top of that, our team is busy completing start-up work for 2 pivotal trials involving pediatric PK deficiency patients. Those trials should begin in mid-2022. I've got more good news as well: on April 14, 2022, the New England Journal of Medicine published findings from the core phase of ACTIVATE, our trial of PYRUKYND in adults who have PK deficiency and aren't on a routine transfusion schedule. Along with ACTIVATE-T, which looked at PK deficiency patients receiving transfusions on a regular basis, that research supported the FDA's recent green light for PYRUKYND in the U.S., and the extension study continues to yield useful information about how the drug performs with longer-term use. At EHA in June, we'll share fresh PRO findings from ACTIVATE, results demonstrating that hemoglobin levels return to normal after extended PYRUKYND treatment, and additional data on comorbidities and complications coming out of the PEAK Registry. Beyond PK deficiency, we believe that activating PK may play a meaningful part in managing thalassemia as well as sickle cell disease. Toward the end of last year, we began our pair of worldwide placebo-controlled pivotal studies of PYRUKYND for thalassemia, known as ENERGIZE and ENERGIZE-T. To recap, ENERGIZE is set to evaluate 171 patients assigned randomly in a 2:1 ratio to either 100 milligrams of mitapivat taken twice daily or a placebo, including individuals with alpha and beta thalassemia who do not receive routine transfusions. The main goal is hemoglobin response, which is characterized as an increase of at least 1 gram per deciliter in average hemoglobin concentration from week 12 through week 24 relative to baseline. In ENERGIZE-T, a total of 240 participants will be enrolled and assigned in a 2:1 ratio to receive either 100 milligrams of mitapivat twice per day or a placebo. This study includes individuals with both alpha and beta thalassemia who undergo routine transfusions—meaning they received between 6 and 20 units of red blood cells across the 24 weeks before being randomized. The main goal being measured is transfusion reduction response, which means achieving at least a 50% decrease in the number of red blood cell units transfused, along with a drop of 2 or more units of transfused red blood cells during any 12 consecutive weeks up to week 48, when compared with Phase I. During the past year, we kicked off the Phase II segment of our Phase II/III trial for sickle cell disease, known as RISE UP. In that study, 69 participants will be assigned randomly in a 1:1:1 ratio to receive either 50 milligrams of mitapivat two times a day, 100 milligrams of mitapivat two times a day, or a matching placebo. What we're primarily evaluating includes hemoglobin response—defined as a rise of no less than 1 gram per deciliter in mean hemoglobin levels between week 10 and week 12 compared with the starting point—as well as the adverse events that arise; these findings will guide us in establishing a definitive dosing strategy for the Phase III segment. Our group continues to be committed to driving forward with site activation around the world and patient enrollment in all 3 studies. AG-946 is our novel PKR activator, and it's currently under evaluation in a Phase I study. After hitting a maximum tolerated dose, we recently wrapped up the single ascending and multiple ascending dose cohorts in healthy volunteers. Because of that, we've determined which doses we'll advance into the Phase I sickle cell disease cohort and the MDS Phase IIa trial; we're eager to share updated data from the SAD and MAD cohorts at a medical meeting coming up. Beyond that, we've opened sites for the sickle cell disease cohort and expect to enroll the first patient before long. Just to remind everyone, the sickle cell arm exists to gather data in patients who have hemolytic anemia. In addition, we are moving forward with activating the 2A segment of the Phase IIa/IIb trial of AG-946 in MDS. This Phase IIa component is designed as an open-label proof-of-concept evaluation of a single dose level of AG-946 among individuals with lower risk myelodysplastic syndrome. Enrollment will consist of 20 patients in total, and each will take AG-946 once per day for the full 16-week core period. Patients completing that core period will have the option to continue into an extension period. This study's main goals are, first, hemoglobin response—meaning a rise of no less than 1.5 grams per deciliter above the starting level in average hemoglobin concentration between weeks 8 and 16—and second, transfusion independence, meaning a stretch of at least 8 straight weeks with no transfusion throughout the core period, and this applies only to those patients whose transfusion burden is low. Safety, other measures of anemia, and PK and PD biomarkers make up the secondary endpoints. We can't wait to see this trial get underway before the year is out. With that, I'll pass things to Richa, who serves as our Chief Commercial Officer.

Richa Poddar

executive
#4

Thank you, Sarah. It's a pleasure to share our initial quarterly update on the PYRUKYND launch, during which we achieved $832,000 in net U.S. sales across the first 6 weeks following our February 17 approval. As we've noted previously, our approach to commercialization centers on engaging patients and informing providers so that, first, patients receive an accurate diagnosis through initiatives such as Anemia ID; second, doctors recognize the urgency to prescribe while eligible patients speak up for treatment; and lastly, patients link up with myAgios Support Services to sharpen that understanding, secure access, and encourage long-term adherence to medication. Having spent the past couple of months in the field, the discussions we've had with patients, physicians, and caregivers keep highlighting the value we believe PYRUKYND delivers to people living with this disease, and we're encouraged that we have a chance to make a genuine difference in these patients' lives through a first-in-class disease modifying therapy. During the early days of launch, we've picked up meaningful insights that further confirm the effectiveness of our commercial loan strategy. From our mid-February launch through the close of the quarter, our hemolytic anemia specialists have logged over 1,100 customer interactions, building awareness of PYRUKYND and teaching physicians about how this first-in-class PK activator can help adult patients with PK deficiency. This constructive engagement has succeeded in generating prescriptions for patients identified earlier. Our high-touch patient support program, myAgios, has worked effectively with patients and physicians to kick off disease and drug education and to steer through reimbursement hurdles, securing access and reducing abandonment. Beyond that, generating awareness of PYRUKYND within the patient community is a top priority for us. So we've concentrated on building awareness via social media pushes, word of mouth, patient webinars, myAgios, and collaborations with patient advocacy groups; these efforts are paying off, since PK deficiency patients have proven to be tremendous self-advocates, and proactive patient requests for PYRUKYND have sped up early prescribing. On the payer side, our national account directors have enjoyed dozens of positive interactions with payers so far. As we expected, these early approvals have come through the medical exception process, while prior authorization and utilization management criteria are being developed across fares. And last, regarding Anemia ID, we continue to see robust interest, with over 3,500 kits ordered since the program began. Among the completed tests, which still represent only a portion of all kits ordered, the PK deficiency positivity rate sits in the mid-single-digit percentages and falls within the range we would have anticipated. As a reminder, Anemia ID was created for patients with a general diagnosis of hemolytic anemia of unknown etiology and isn't specific to PK deficiency. As we've said before, physicians keep appreciating the benefit this program provides to their patients, which fuels our longer-term strategy of continuing to ensure accurate diagnosis, enabling a higher diagnosis rate over time. These first launch results have us feeling quite positive, along with the good experiences we're building across a wider PK deficiency community. Still, we need to keep in mind that PK deficiency is an uncommon, long-term illness that isn't well comprehended. Making sure we succeed over a longer horizon depends above all on our work in disease education and finding patients. Even with the persistent difficulties brought by the pandemic, which have forced us to engage almost entirely virtually, the commercial team remains completely dedicated to these efforts. That's tough in a disease area where you need many touchpoints both to teach people about the illness so they feel urgency and to confirm an accurate diagnosis. As we move through these initial quarters, we'll gain a clearer picture of how the launch is tracking. Drawing on what we've done so far, we still think there are roughly 1,500 to 4,000 patients with PK deficiency in the U.S., which translates to peak U.S. revenue potential of $200 million to $225 million. We've assembled a committed commercial group with deep rare disease expertise, entirely able to carry out our launch plan, and we're thrilled and thankful for the difference we're making in the lives of those with PK deficiency. What matters greatly is that this first quarter has shown us that our commercial approach, our accumulated knowledge, and the relationships we're forming are positioning us well as we keep broadening PYRUKYND's use to every eligible PKD patient and, further out, to other diseases defined genetically. On its own, with PK deficiency and thalassemia, PYRUKYND could become a global blockbuster therapy. With that, I'll hand things over to Jonathan, who will walk through the first quarter financials.

Jonathan Biller

executive
#5

Thank you, Richa. You can find our financial results for the first quarter of 2022 in the press release that went out this morning, and I'll give you a summary of those. Additional specifics will appear in our 10-Q filing that comes later today. As Richa mentioned, PYRUKYND revenue during the first quarter came to $832,000. Cost of sales for that quarter was $339,000. Now moving to operating expenses. Research and development for the first quarter totaled $70.1 million, which is an increase of $12.5 million over the first quarter of 2021. The rise in R&D year over year was mainly attributable to start-up costs for the PYRUKYND pivotal studies in thalassemia and sickle cell disease along with planned increases in preclinical activities, partly offset by closeouts of the ACTIVATE and ACTIVATE-T studies. Selling, general and administrative expenses came in at $31.5 million for the first quarter, a decrease of $2 million versus the first quarter of 2021. The drop in SG&A expense largely reflected lower workforce-related spend. TIBSOVO royalty revenue, recorded under royalty income from gain on sale of oncology business on our income statement, was $2.7 million. We closed the quarter with cash, cash equivalents and marketable securities of roughly $1.2 billion. Given this cash balance, we believe we can carry out our current operating plan through major catalysts and to cash flow positivity without needing to raise additional equity; in today's environment, we appreciate having such a strong balance sheet, while also being mindful to preserve this advantage and secure the capital required to execute on our promising clinical programs and retain flexibility for business development. So, as we start our annual long-range planning process, which we kick off in the early spring of each year, we remain laser focused on capital allocation to only our highest priority as well as continuing to proactively manage our expense base; with that, operator, please open the line for questions.

Anupam Rama

analyst
#6

Regarding reimbursement for PYRUKYND, what trends are you observing? Also, what are you seeing when it comes to the duration from a script being written to a patient actually starting therapy? And what about the phenotype of the first patients beginning treatment — how severe are they, are they transfusion dependent, and similar factors?

Richa Poddar

executive
#7

Anupam, thanks for asking. On the reimbursement side, our initial discussions with payers have been quite favorable. From a reimbursement perspective, as we anticipated, most of the approvals have come through the medical exception pathway. We anticipate this will remain the case during the second quarter too, until payable policies get established. So on the whole, I'd describe us as on track and performing precisely as we had anticipated. Payer policies continue to be worked out everywhere; thus it's genuinely premature to speak about the particulars of prior authorization or utilization management criteria, though we ought to have those details within the next few quarters. So keep watching for further updates there. As for your inquiry about patient types, it's highly consistent with what we'd anticipate from the broader adult PKD population. We aren't observing heavy usage among one particular category of PKD patient — what we're seeing matches expectations. Because treatment choices are so scarce, the unmet medical need is enormous, and this is the first approved therapy, it's being used among many different patient categories: those not regularly transfused, the regulatory transfused patients, younger patients, older patients, and patients experiencing assorted symptoms. So it's quite representative of the overall patient population.

Marc Frahm

analyst
#8

Congratulations on getting it out early. Did stocking play any role at all during the quarter? Or does that $800,000 reflect genuine demand across the handful of weeks you had once approval came through? And then, thinking more widely about the last 3 months, was there an early surge of demand showing up in start forms? Or have start forms instead climbed gradually across roughly the past 3 months following approval?

Richa Poddar

executive
#9

Yes. I'll take your second question. Regarding the broader picture, there was no surge — things have gone the way we anticipated. As patients arrive, when they have appointments scheduled with physicians, they begin therapy. We're guiding them through, they get linked with the myAgios Patient Support program, and from there they move through the access steps. So it lines up very, very closely with what we expected initially. So nothing like, oh, everybody's rushing to obtain the drug — quite similar to what we anticipated, simply because of how this disease works; and you'll keep seeing the continuing effects of the pandemic, and given that this is a rare chronic condition, prioritization still occurs in the sense that not — physicians aren't proactively reaching out to patients or holding out for the appointment. Staff need to keep educating about the disease and building awareness among both patients and physicians regarding the disease along with the therapy's availability. So that has matched our initial expectations very closely. As for your questions about the $832,000, that figure appears because we record sales according to orders received from our distribution partners. So fluctuations will happen, again, first quarter, early in the quarter, correct? So once we gain a clearer picture of how things overall will unfold, we ought to be able to offer you improved guidance. But at this point, that number reflects the — it's a combination, right? It takes some time to get scripts going and then secure approval too. But this gets recorded according to orders placed by distribution partners.

Marc Frahm

analyst
#10

Marc, thanks — glad that was useful. Now, regarding 964, you mentioned that MTD had been identified. Could you take us back through which adverse events led to that maximally tolerated dose determination?

Jacqualyn Fouse

executive
#11

Absolutely. As one would anticipate in a Phase I trial, we escalate the dose as high as possible, and what we found was a dose-limiting toxicity in the form of thrombocytopenia. No other clinical adverse event accompanied it, and it was quite easy to monitor and manage, since all parameters went back to baseline once the drug was stopped. From those data, we could also pin down the doses, given that we had already achieved the pharmacodynamic effects we were looking for. That allowed us to establish a safe dose for patients with sickle cell disease and for MDS patients, neither of whom experienced these events. We're really enthusiastic about that. On the operational side, both the sickle cell disease portion of the Phase I and the MDS portion are progressing nicely.

Greg Harrison

analyst
#12

Could you discuss the number of patients who have begun treatment with PYRUKYND? Also, regarding the early launch phase, what should we anticipate for metrics such as patient starts, discontinuations, therapy duration, and similar items?

Richa Poddar

executive
#13

Sure. At this point, Greg, we aren't providing detailed figures regarding patients who have initiated. Launch is still at a very, very early stage, correct, and this is an uncommon chronic illness. Therefore, to assist you in modeling properly, our aim is to examine patterns as they emerge over time and offer a clearer picture once we understand how those patterns are shaping up. As mentioned previously, at present, the majority of approvals go through the payer process via the medical exception process, so that is taking some time since we need to ensure that proper payer policies can be established and patients can gain access over the long term; thus our approach is succeeding, we are observing that, and we keep having constructive engagements that reflect the excitement, as expected, from the patient community and from the physician community regarding this treatment. So keep watching for additional updates in upcoming quarters. It remains too soon to say.

Jacqualyn Fouse

executive
#14

This is Jackie speaking. I was merely about to — what I mean is, we are observing a pleasant, consistent movement, and matters are unfolding as we anticipated they would, exactly like Richa mentioned. Consequently, prescriptions are in the process of being composed. In fact, we are already observing refills. Thus, this, in my view, demonstrates a pleasant momentum, since we have only completed the second full — well, we are now entering the third complete month since launch. Additionally, I would simply like to remind everyone that we are utilizing 1 specialty pharmacy; therefore, this is not a scenario in which there exists, say, a certain kind of enormous distribution network for which you are stocking up a pipeline. So I just want that to be plain. And apologies, I did not intend to cut you off.

Greg Harrison

analyst
#15

Yes, that helps. My other question was whether you've — I realize it's quite early, but has there been any discernible uptick in awareness of the disease? And how do you anticipate diagnosis rates will be affected as more people learn a treatment exists?

Richa Poddar

executive
#16

On the awareness side, I'd say the trend is moving in a favorable direction; we'll share updates as data accumulates over time, since, as you're aware, this has only been the initial partial quarter since launch. As for diagnosis rate, tracking that requires a span of a few years, correct? So you wouldn't anticipate us to offer updates on it on a quarterly cadence, necessarily. What I will mention is that our work related to Anemia ID matters a great deal; and the reason we remain — we feel quite encouraged by the enthusiasm we're seeing for that program is that it's the sole avenue at our disposal to genuinely assist with both our education efforts and to help secure accurate diagnosis, which will allow longer-term gains in the diagnosis rate. That way we keep witnessing consistent expansion and sustained interest. So that's thrilling for us, and it will stay a priority.

Mark Breidenbach

analyst
#17

Nice work on getting it launched. I just have a couple of quick things. Should we be expecting that cost of sales, as a share of revenue, will decline somewhat over the coming quarters? What I'm really trying to get at is where you think that figure might level off. Also, regarding SG&A this quarter, it came in fairly level compared with the prior quarter — does that suggest the entire commercial buildout and every hire required to back the PYRUKYND launch are now in place?

Jonathan Biller

executive
#18

Mark, this is Jonathan. I'll handle your questions one at a time. On cost of goods, absolutely — as volumes climb, you'll watch cost of goods decline, since our fixed costs get leveraged more effectively once demand rises and the launch moves forward. That figure is going to drop. It's also a small molecule, so in the end you ought to see gross margins that are very healthy, comparable to what TIBSOVO delivered for you. Turning to SG&A, yes — we put in a lot of effort last year, and we continue working to ensure our cost base is right for running the business efficiently and directing our capital toward the top priorities, which means the launch, and we're quite excited about clinical development spanning thalassemia, sickle cell and MDS. Richa has also had her team assembled since roughly the midpoint of last year. That, then, is the run rate you'll observe. Broadly, on OpEx, you should expect fairly steady figures throughout this year. You won't see figures climbing. There will be — some minor quarter-to-quarter movement always happens, yet it ought to stay pretty flat, or in certain quarters it might even dip somewhat. So I think that's a strong signal for what you can roughly model ahead.

Matt Dellatorre

analyst
#19

This is Matt, filling in for Salveen. Could you give us some detail about how things are going with getting people signed up for the Phase II part of RISE UP, ENERGIZE, and ENERGIZE-T? And separately, what clinical catalysts might we anticipate from Agios or its academic partners during this year?

Jacqualyn Fouse

executive
#20

Absolutely. Regarding our ENERGIZE, ENERGIZE-T, and RISE UP trials, we're very pleased to have enrolled the first participants, and our attention is on global site activation and bringing patients into those studies. We don't share particular enrollment figures as we move forward, but we remain on schedule to hit the milestones we previously laid out, so we're quite enthusiastic about the efforts taking place there. And what was the second part of your question? Could you say the second part again, please?

Richa Poddar

executive
#21

This relates to the data catalyst.

Jacqualyn Fouse

executive
#22

The data catalyst, correct. At present, the execution component continues; therefore Phase III ENERGIZE along with ENERGIZE-T remain blinded, and no interim plan exists; as a result, no near-term data catalysts will emerge from those trials. One major item on our side will be the Phase II RISE UP study, scheduled for next year; after that, at EHA, naturally, we have several presentations of data covering findings from throughout our programs, which we are extremely enthusiastic about, and those abstracts are actually due to be released next week. Thus, we are quite thrilled regarding that.

Andrew Berens

analyst
#23

Can you hear me now?

Jacqualyn Fouse

executive
#24

Yes.

Andrew Berens

analyst
#25

Nice work. A couple of things I wanted to ask about the launch. Do you have a sense of the number of prescriptions that produced that $800,000 in revenue? Then I was hoping for more detail on the addressable market you mentioned during the prepared remarks. My recollection is you put it at as many as 4,000 patients in the U.S.; and previously, you've referenced a registry of diagnosed patients numbering roughly 1,100 to 1,200. So those 4,000 patients — are they already identified? Or is that a projected, calculated prevalence figure? And then a question about 946. At the maximum tolerated dose, how far down did platelets drop? And what's known about what causes the thrombocytopenia? To my knowledge, we haven't observed it with the other PKR drugs. And is the effect off target or on target?

Richa Poddar

executive
#26

All right; on your question about prescriptions, we aren't giving specifics there. That $832,000 represented sales to the distributors; with that said, as time passes, they will convert — the reason those sales exist is patient demand, and that demand converts into patient prescriptions over time. So when we have a clearer picture of the broader trends, we'll share that information on a continuing basis. So keep watching for additional updates as we find out more. That said, there are some inventory effects, and again, it's clearly too soon to tell, but as Jackie mentioned as well, we have just a single distributor, so you won't see enormous < > inventory swings occurring. So it does reflect patient demand overall. We'll simply need time to observe that working through. But to be clear, this isn't an accounting matter, it's based on sales to the distributor. So that covers your first question. Your second question, about overall prevalence in PK deficiencies. As we've said on earlier calls, since this is a rare disease, it's poorly understood, not well characterized and chronic, we've needed to collaborate with thought leaders and the wider patient community to genuinely help us figure out what the theoretical prevalence could be for this disease. And we've gathered and triangulated data from numerous different sources, and that gives us confidence that the peak potential for pyruvate kinase deficiency falls within that 1,500 to 4,000 range. But for the purposes of the < >, we ought to use the midpoint of that range, somewhere around that 3,000; and we feel fairly confident in that figure as a theoretical prevalence estimate; that isn't to say we've identified that many patients; we've stated that the diagnosis rate currently sits at roughly 30%, and our efforts, both before launch and ongoing, and they will go on indefinitely in this disease area, have centered on boosting familiarity with the disease and also lifting that diagnosis rate through initiatives such as Anemia ID.

Jacqualyn Fouse

executive
#27

And as we've noted before, our view is that a comparable patient population exists in Europe as well. So I'd put it at — or rather, let's say somewhere between 3,000 and 8,000 across the U.S. and Europe combined, split roughly evenly between the two regions. That means 3,000 in the U.S., which, per Richa, sits around the middle of that range — yet just 30%...

Andrew Berens

analyst
#28

What phenotype would these individuals present with? Do any of them receive transfusions? Which cutoff are you applying?

Richa Poddar

executive
#29

Regarding that cutoff — it's essentially all patients, correct? Every person we think has pyruvate kinase deficiency, according to what we've learned alongside the wider PK deficiency community. Of those, roughly 80% are adults. So nothing leads us to think the grown-up PKD patient group differs from the typical U.S. population. It mirrors that population closely. That's why the breakdown is 80% adult, and that's the group our label covers. You might have heard this from us previously: we're assessing and intend to launch trials among pediatric patients, which would let us serve the full PK deficiency population; however, at present we hold an approval, and the commercial team's attention is on adult PK deficiency, reflecting that 80%; so in general, just — that's the hypothetical prevalence tied to disease education and building awareness around the therapy's approval. Both efforts are happening as we speak.

Jacqualyn Fouse

executive
#30

Now, turning to your questions about 946. This was a Phase I trial where we escalated the dose quite a bit. The event we saw occurred at a level we have no plans to administer. As for what possible hypothesis might explain it, we have given that thought. However, since those are doses we won't be using, further investigation isn't something we intend to pursue, particularly given that this event can be monitored and managed quite easily, and the physicians actually treating the diseases we're studying are at ease handling such situations too; for example, we have not seen thrombocytopenia in the setting of PYRUKYND; therefore, that won't appear in our label. And regarding 946, as I said, the doses we picked are below the one at which this was observed, and those studies remain on schedule to begin.

Alex Nackenoff

analyst
#31

Alex Nackenoff here, filling in for Danielle. I've got a question about Anemia ID. You mentioned 3,500 kits. Have all of those kits actually been filled, or are they just ordered — or have they truly been processed? Also, do you have information that would let you say how many of the patients identified in the hit rate have gotten a prescription or begun treatment? Then one more detail on 946: could you disclose the maximum tolerated dose in the healthy volunteers and/or the doses picked for the SAD cohort?

Richa Poddar

executive
#32

Yes. Regarding Anemia ID, as we said, 3,500 kits were ordered, but just a quarter are complete. So physicians might order kits knowing patients will visit their practice later on. So not every one of them is complete. And as we noted in our remarks, the positivity rate sits around mid-single digits, which is again right in line with what we expected, since Anemia ID is built for hemolytic anemia of unknown etiology and isn't specific to PK deficiency — we anticipated it would land in that mid-single-digit range. So nothing there is surprising either. What encourages us is both the value this proficiency brings their patients and the fact that we keep seeing strong interest in the program and utilization. As for directly converting a patient found through Anemia ID into a script, that process takes some time, right? You find the patient, then you must locate the physician who has that patient, and the physician has to call the patient in, the patient has to be willing to come in, and all of that. So we've been tracking this and keeping a draft of every patient found through the program, and making sure we connect with the physicians, knowing they may have found a patient. Those conversations usually lead to a script, but you can't just go direct. Time has to pass before that happens.

Jacqualyn Fouse

executive
#33

Now, about what you asked concerning the dose. All the specifics of our healthy volunteer study are going to be shared by us at a medical meeting that's coming up. As for the dose chosen for sickle cell disease and MDS, here's what I'm able to say: for sickle cell disease, the protocol had already been written, and the same is true for MDS, and none of our criteria for selecting the dose were altered because of the events that were observed.

Jacqualyn Fouse

executive
#34

Thanks, operator, and thanks to all of you for your questions today. As I always do, I want to express appreciation to my Agios teammates for the commitment and enthusiasm they bring to improving patients' lives. I'd also like to express gratitude to every patient, caregiver and physician who works alongside us in so many ways, particularly those taking part in our clinical trials across all indications. The ties we share with all of our stakeholders, and the work we do jointly, drive continued innovation and impact for individuals living with genetically-defined diseases. Thanks for being with us today. You may now disconnect.

Operator

operator
#35

That brings our presentation for today to a close, everyone. You're welcome to leave the call now, and we hope the rest of your day is great.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Agios Pharmaceuticals, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Agios Pharmaceuticals, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Agios Pharmaceuticals, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.